Supplement
Andrographolide inhibits NF-κB activation, stimulates interferon production, inhibits platelet aggregation, and modulates PPAR-γ for anti-inflammatory and immunostimulatory effects.[1888,2001,2816, etc.]
Superscript reference numbers link to the Sources bibliography.
Composite Rating
Blends evidence depth, community direction, safety friction, and completeness.
Evidence Intensity
45/100
Moderate depth from human/RCT/meta counts
Community Direction
9
Mixed / Neutral • confidence Moderate
Safety Friction
0/100
Sparse signal from adverse/interaction markers
Data Completeness
100%
Studies 3 • mentions 8 • links 5
Not medical advice. This product is for educational and informational purposes only. It does not diagnose, treat, cure, or prevent any disease and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition.
FDA disclaimer: These statements have not been evaluated by the Food and Drug Administration. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. Results may vary. Not intended for use by pregnant or nursing women, individuals under 18, or those with known medical conditions without physician consultation.
If you are experiencing a medical emergency, call 911 or your local emergency number immediately.
Goal alignment: Immune Support, Respiratory, Inflammation.[1888,2001,2816, etc.]
Dose guide: 200-400 mg extract standardized to 30-50 mg andrographolide daily.[1888,2001,2816, etc.]
Category
Botanical
Evidence Tier
EXPLORATORY
Daily Guide
200-400 mg extract standardized to 30-50 mg andrographolide daily
Clinical Depth
Humans: 3 • RCTs: 2 • Meta: 1
Cohort / Real-World
Cohort signals: 0
Safety Markers
Adverse signals: 0 • Interactions: 0
Freshness, trend, and study timeline for this item
Status
Trend
· Limited trend data
Depth
3 total studies
Timeline
Total indexed
3
Human studies
3
Randomized trials
2
Meta-analyses
1
Cohort signals
0
Mechanistic signals
0
Weighted direction score: 9 (Mixed / Neutral)
Total indexed
3
Human studies
3
Randomized trials
2
Meta-analyses
1
Cohort signals
0
Mechanistic signals
0
Distribution of evidence by study design strength
Evidence Strength: Moderate
Composite of study volume, RCTs, and meta-analyses
PMID 28679908 • 2017
Andrographis and upper respiratory infections: Cochrane review
META_ANALYSIS
Open PubMedPMID 20839210 • 2010
Andrographis for common cold: a double-blind RCT
RCT
Open PubMedPMID 19100322 • 2009
Andrographis and rheumatoid arthritis: a pilot RCT
RCT
Open PubMedBenefit reports: 4
Adverse reports: 3
No-effect reports: 0
Mixed reports: 1
Unclear reports: 0
Signal confidence: 0.58
Benefits
Adverse
No Effect
The Cochrane review for URI support gives this unusual credibility for an herb. Best used at first sign of cold/flu as acute therapy.
aggregate • benefit
Aggregate community signal: 8 directional mentions (benefit 4, adverse 3, no-effect 0, mixed 1).
Open mentionamazon
Amazon search for Andrographis (Andrographis paniculata)
Rating: n/a | Reviews: n/a
Open productEvidence Sources
PUBMED • 2017 • Human evidence curation set
PMID 28679908 from META_ANALYSIS.
Outcome: See linked PubMed abstract for methods and outcomes.[1888,2001,2816, etc.]
Open sourcePUBMED • 2010 • Human evidence curation set
PMID 20839210 from RCT.
Outcome: See linked PubMed abstract for methods and outcomes.[1888,2001,2816, etc.]
Open sourcePUBMED • 2009 • Human evidence curation set
PMID 19100322 from RCT.
Outcome: See linked PubMed abstract for methods and outcomes.[1888,2001,2816, etc.]
Open source